## Orsiro® Mission DES

Even better deliverability for the outstanding Orsiro DES<sup>1</sup>



The next level of deliverability<sup>1</sup>






Ultrathin struts<sup>2</sup>





Outstanding patient outcomes<sup>3</sup>





## Orsiro® Mission DES **NEW** NFW More flexible shaft Deep embedding for high track for high cross Orsiro Mission 3.0/22 06185400-08 BI0lute<sup>1</sup> )00 proBIO<sup>T</sup> Enhanced force **Dual-coating** Bioabsorbable Ultrathin Passive coating 60 μm\* struts on shaft for Ergonomic hub for high transmission coating limited friction biocompatibility with kink resistance for high push with controlled drug for early release and low5 endothelialization thrombogenicity The next level of deliverability **Outstanding patient outcomes** Better push, track and cross<sup>1</sup> Clinically proven Orsiro DES<sup>4,6,7,8</sup> BIOFLOW-V, FDA pivotal trial (n = 1,334) Cumulative incidence-TLF (%) 100 TLF out to 36 months — Xience 13.6 80 12 - Orsiro 11.1 9.2 8.2 7.1 ■ Orsiro Mission 5.9 ■ Xience Sierra ■ Synergy 20 ■ Resolute Onyx p = 0.032p = 0.015p = 0.002Pushability Trackability Crossability 12 18 24 30 Time after initial procedure (months)

TLF = Target Lesion Failure. \*ø 2.25 mm - 3.0 mm; ♦ Based on 36-m frequentist analysis.

1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability, BIOTRONIK data on file; 2. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis; 3. Based on investigator's interpretation of BIOFLOW-V primary endpoint result; 4. Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020, doi: 10.1016/j.jcin.2020.02.019; 5. Per investigators' interpretation of preclinical studies with Orsiro as mentioned in Cassese et al. J Thorac Dis 2018;10[2]:688-692; 6. Kandzari D et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions Science. Presentation at E SC 2017; 8. Kandzari D et al. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents: Journal of American College of Cardiology (2018), doi: https://doi.org/10.1016/j.jac.2018.09.019.

Clinical data conducted with Orsiro, Orsiro Mission's predecessor device can be used to illustrate Orsiro Mission clinical outcomes.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies. Xience Sierra is a trademark of the Abbott Group of Companies; Synergy is a trademark of Boston Scientific; Resolute Onyx is a trademark of Medtronic Vascular Inc.